Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Production and application of LPA polyclonal antibody.

Chen JH, Zou F, Wang ND, Xie SW, Zhang X.

Bioorg Med Chem Lett. 2000 Aug 7;10(15):1691-3.

PMID:
10937726
2.

Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction.

Chen X, Yang XY, Wang ND, Ding C, Yang YJ, You ZJ, Su Q, Chen JH.

Scand J Clin Lab Invest. 2003;63(7-8):497-503.

PMID:
14743959
3.

Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.

Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR.

Cancer Treat Res. 2002;107:259-83. Review.

PMID:
11775454
4.
5.

Lysophosphatidic acid and its role in reproduction.

Budnik LT, Mukhopadhyay AK.

Biol Reprod. 2002 Apr;66(4):859-65. Review.

PMID:
11906902
6.
7.

Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.

Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, Jaffe RB.

J Natl Cancer Inst. 2001 May 16;93(10):762-8.

PMID:
11353786
8.

The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.

Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB.

Cancer Res. 2003 Mar 1;63(5):1073-82.

9.

Lysophospholipids are potential biomarkers of ovarian cancer.

Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K, Griffin D, Blanco RW, Cantor AB, Xiao YJ, Krischer JP.

Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1185-91.

10.

Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.

Schwartz BM, Hong G, Morrison BH, Wu W, Baudhuin LM, Xiao YJ, Mok SC, Xu Y.

Gynecol Oncol. 2001 May;81(2):291-300.

PMID:
11330965
11.

[Application of dot immunogold filtration assay in antibody detection for cysticercosis].

Liu ZP, Li H, Zhu LY, Liu S, Xue HC.

Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2001;19(6):354-6. Chinese.

PMID:
12572070
12.

Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.

Hu YL, Albanese C, Pestell RG, Jaffe RB.

J Natl Cancer Inst. 2003 May 21;95(10):733-40.

PMID:
12759391
13.

Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.

Figini M, Martin F, Ferri R, Luison E, Ripamonti E, Zacchetti A, Mortarino M, Di Cioccio V, Maurizi G, Allegretti M, Canevari S.

Cancer Immunol Immunother. 2009 Apr;58(4):531-46. doi: 10.1007/s00262-008-0575-5. Epub 2008 Aug 15.

PMID:
18704410
14.

Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells.

Sawada K, Morishige Ki, Tahara M, Ikebuchi Y, Kawagishi R, Tasaka K, Murata Y.

Gynecol Oncol. 2002 Dec;87(3):252-9.

PMID:
12468322
15.

The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.

Wang P, Wu X, Chen W, Liu J, Wang X.

Gynecol Oncol. 2007 Mar;104(3):714-20. Epub 2007 Jan 3.

PMID:
17204312
16.

Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer.

Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H, Kishi Y, Yamaguchi H, Sasaki S, Sako A, Konishi T, Arai H, Nagawa H.

Lab Invest. 2004 Oct;84(10):1352-62.

17.

Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer.

Goetzl EJ, Graeler M, Huang MC, Shankar G.

ScientificWorldJournal. 2002 Feb 6;2:324-38. Review.

18.

[Preparation and preliminary application of rabbit polyclonal antibodies against intracellular peptides of human platelet glycoprotein GPIbalpha].

Yuan YH, Kang JR, Yan R, Cheng H, Zhuang FY, Wang YD, Dai KS.

Zhonghua Yi Xue Za Zhi. 2009 Mar 31;89(12):826-30. Chinese.

PMID:
19595123
19.

Negative purification method for the selection of specific antibodies from polyclonal antisera.

Benet C, Van Cutsem P.

Biotechniques. 2002 Nov;33(5):1050, 1052-4.

PMID:
12449383
20.

Supplemental Content

Support Center